PARP1 and cancer: PARP inhibitor efficacy may also be influenced by the TME, with hypoxia proposed to be both a sensitizer of HR-proficient cells to PARP inhibitors, as well as a barrier to PARP inhibitor efficacy in HRD cell lines from various cancers.